** Shares of drug developer Tectonic Therapeutic TECX.O rise ~104% to $52.50, set for record single-day pct gain
** TECX says its experimental drug, TX45, showed improved blood flow and reduced pressure in lungs and heart in an early-stage trial
** TECX is testing TX45 to treat patients with group 2 pulmonary hypertension, a condition where high lung blood pressure is caused by left-sided heart disease, leading to symptoms such as shortness of breath, fatigue, and swelling in the legs and feet
** TX45 was well-tolerated and had no serious side effects in patients - TECX
** The condition currently has no approved treatments
** TECX more than doubled in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。